A Melbourne startup is betting that the future of medicine is catching illness before it starts — and investors are backing that vision with serious money.
Everlab, which is building an AI-powered preventive healthcare platform, has closed a AU$65 million Series A funding round, according to SmartCompany. The round was led by Airtree Ventures, one of Australia's most prominent venture capital firms. The company is using the capital to expand its preventive health offering.
Preventive healthcare — the idea of monitoring and intervening before disease develops, rather than treating it after the fact — has long been seen as the holy grail of modern medicine. It promises to reduce long-term costs, improve quality of life, and ease pressure on overburdened health systems. But scaling that kind of proactive care has historically been difficult and expensive.
Everlab's approach leans on artificial intelligence to make that model more practical and accessible. By automating analysis and surfacing insights that might otherwise require extensive specialist time, AI platforms like Everlab's aim to bring personalised preventive care within reach of a broader population.
The AU$65 million raise is a significant vote of confidence in both the company and the broader preventive health sector at a time when AI is reshaping how healthcare is delivered. If platforms like Everlab can deliver on the promise, the implications for how we manage long-term health — and the costs that come with it — could be substantial.